Literature DB >> 24319186

Bringing natural killer cells to the clinic: ex vivo manipulation.

Richard W Childs1, Maria Berg.   

Abstract

Recently, there has been a substantial gain in our understanding of the role that natural killer (NK) cells play in mediating innate host immune responses against viruses and cancer. Although NK cells have long been known to be capable of killing cancer cells independently of antigen recognition, the full therapeutic potential of NK cell-based immunotherapy has yet to be realized. Here we review novel methods to activate and expand human NK cells ex vivo for adoptive transfer in humans, focusing on the important phenotypic and functional differences observed among freshly isolated, cytokine activated, and ex vivo-expanded NK populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24319186      PMCID: PMC6610030          DOI: 10.1182/asheducation-2013.1.234

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  71 in total

1.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

Review 2.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

3.  IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Authors:  Don M Benson; Courtney E Bakan; Shuhong Zhang; Shauna M Collins; Jing Liang; Shivani Srivastava; Craig C Hofmeister; Yvonne Efebera; Pascale Andre; Francois Romagne; Mathieu Bléry; Cécile Bonnafous; Jianying Zhang; David Clever; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

4.  Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.

Authors:  Tina Müller; Christoph Uherek; Guitta Maki; Kai Uwe Chow; Annemarie Schimpf; Hans-Georg Klingemann; Torsten Tonn; Winfried S Wels
Journal:  Cancer Immunol Immunother       Date:  2007-08-24       Impact factor: 6.968

5.  A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.

Authors:  S Carlens; M Gilljam; B J Chambers; J Aschan; H Guven; H G Ljunggren; B Christensson; M S Dilber
Journal:  Hum Immunol       Date:  2001-10       Impact factor: 2.850

6.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

7.  Replicative potential of human natural killer cells.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Chihaya Imai; Charles G Mullighan; Dario Campana
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

8.  Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.

Authors:  Dan Zhu; Laura G Corral; Yuedi W Fleming; Bernd Stein
Journal:  Cancer Immunol Immunother       Date:  2008-04-08       Impact factor: 6.968

9.  Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.

Authors:  Jan Spanholtz; Frank Preijers; Marleen Tordoir; Carel Trilsbeek; Jos Paardekooper; Theo de Witte; Nicolaas Schaap; Harry Dolstra
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

10.  IL-18-induced CD83+CCR7+ NK helper cells.

Authors:  Robbie B Mailliard; Sean M Alber; Hongmei Shen; Simon C Watkins; John M Kirkwood; Ronald B Herberman; Pawel Kalinski
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  51 in total

1.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

Review 2.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

Review 3.  Umbilical cord blood graft engineering: challenges and opportunities.

Authors:  P A Thompson; K Rezvani; C M Hosing; B Oran; A L Olson; U R Popat; A M Alousi; N D Shah; S Parmar; C Bollard; P Hanley; P Kebriaei; L Cooper; J Kellner; I K McNiece; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

4.  Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.

Authors:  Markus Granzin; Ana Stojanovic; Matthias Miller; Richard Childs; Volker Huppert; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

Review 5.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

6.  A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

Authors:  Sumithira Vasu; Maria Berg; Jan Davidson-Moncada; Xin Tian; Herb Cullis; Richard W Childs
Journal:  Cytotherapy       Date:  2015-11       Impact factor: 5.414

7.  Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy.

Authors:  Huiying Yu; Wei Chen; Changling Li; Di Lin; Junde Liu; Zien Yang; Jingang Yang; Yinghui Sun; Dongchu Ma
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

8.  In Vivo Tracking of Adoptively Transferred Natural Killer Cells in Rhesus Macaques Using 89Zirconium-Oxine Cell Labeling and PET Imaging.

Authors:  Peter L Choyke; Richard W Childs; Noriko Sato; Kate Stringaris; Jan K Davidson-Moncada; Robert Reger; Stephen S Adler; Cynthia Dunbar
Journal:  Clin Cancer Res       Date:  2020-02-07       Impact factor: 12.531

9.  Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Authors:  Diego Sánchez-Martínez; Gemma Azaceta; Aura Muntasell; Nacho Aguiló; David Núñez; Eva M Gálvez; Javier Naval; Alberto Anel; Luis Palomera; Carlos Vilches; Isabel Marzo; Martín Villalba; Julián Pardo
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

Review 10.  Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.